Immutep LAG-3 Inhibitor May Have Path Forward

 
• By Joseph Haas
3d illustration of T cells attacking a cancer cell
Immutep thinks its LAG-3 inhibitor can improve immune response for PD-1 agents

More from Clinical Trials

More from R&D